坤泰胶囊治疗卵巢储备功能减退:随机对照试验的系统评价与Meta分析
该系统评价纳入12项随机对照试验共905例卵巢储备功能减退患者,比较坤泰胶囊单用或联合激素治疗与激素治疗单用的疗效。Meta分析显示,联合治疗在提高窦卵泡计数和抗苗勒管激素水平方面优于激素治疗单用,坤泰胶囊单用可改善窦卵泡计数;但纳入试验存在方法学质量问题,需进一步规范研究。
要点
- 坤泰胶囊联合激素治疗可提高DOR患者窦卵泡计数和抗苗勒管激素水平。
- 坤泰胶囊单用可改善DOR患者窦卵泡计数。
- 纳入试验方法学质量存在问题,结论需谨慎解读。
核心结论
- 基于现有结果,坤泰胶囊联合激素治疗可能改善DOR患者的窦卵泡计数、抗苗勒管激素和促卵泡激素水平。
- 坤泰胶囊单用可能改善DOR患者的窦卵泡计数和促卵泡激素水平。
- 纳入试验存在方法学质量问题,需要进一步开展标准化研究。
研究设计与样本
- 系统评价与Meta分析,检索中国知网、万方、维普、中国生物医学文献数据库、PubMed、Cochrane Library和Embase从建库至2023年7月。
- 纳入比较坤泰胶囊与激素治疗、坤泰胶囊联合激素治疗与激素治疗单用治疗DOR的随机对照试验。
- 采用RoB 1.0评估偏倚风险,使用RevMan 5.4软件进行Meta分析。
- 共纳入12项随机对照试验,涉及905例DOR患者。
主要发现
- 坤泰胶囊联合激素治疗在提高窦卵泡计数方面优于激素治疗单用(MD=1.34,95%CI[0.96,1.72])。
- 坤泰胶囊联合激素治疗在提高抗苗勒管激素水平方面优于激素治疗单用(MD=1.09 ng/mL,95%CI[0.80,1.38])。
- 坤泰胶囊单用对比激素治疗单用,在改善窦卵泡计数方面有改善(MD=0.65,95%CI[0.48,0.83])。
关键数值与推荐
- 主要结局指标为窦卵泡计数和血清抗苗勒管激素,次要结局指标为促卵泡激素和不良反应。
临床怎么用
- 对于DOR患者,可考虑坤泰胶囊联合激素治疗以改善窦卵泡计数和抗苗勒管激素水平。
- 坤泰胶囊单用可能作为改善窦卵泡计数的选择,但需结合患者具体情况。
局限性
- 纳入试验存在方法学质量问题,可能影响结论可靠性。
- 需要进一步开展标准化、高质量的研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Diminished ovarian reserve (DOR) results in reduced fertility. Kuntai capsule, a Chinese patent medicine, which can nourish the heart and kidneys, has shown promising efficacy in its treatment. However, there is no enough clinical evidence to confirm the efficacy and safety of Kuntai capsule. AIM OF THE STUDY: This review aims to evaluate Kuntai capsule's potential benefits and detriments for diminished ovarian reserve. MATERIALS AND METHODS: Databases namely China National Knowledge Infrastructure, WANFANG Database, Chinese Science and Technology Journal Database, Chinese Biomedical Literature Database, PubMed, Cochrane Library, and Embase were searched from their inception to July 2023. We included randomized controlled trials (RCTs) comparing Kuntai capsule to hormone therapy (HT) and Kuntai capsule in combination with HT to HT alone for DOR treatment. The risk of bias was evaluated using RoB 1.0. A Meta-analysis was performed using RevMan 5.4 software. The primary outcomes were antral follicle count (AFC) and serum anti-Müllerian hormone (AMH), secondary outcomes were follicle-stimulating hormone (FSH) and adverse reactions. RESULTS: A Meta-analysis of 12 randomized controlled trials (RCTs), encompassing a total of 905 DOR patients was conducted. The results indicated that the combination of Kuntai capsule with HT exhibited superior efficacy in enhancing AFC (MD = 1.34, 95% CI [0.96,1.72]) and AMH levels (MD = 1.09 (ng/mL) 95% CI[0.80,1.38]), Kuntai capsule demonstrated improvements in AFC (MD = 0.65, 95% CI [0.48,0.83]) in DOR patients compared to HT alone. CONCLUSIONS: Based on the available results, the combination of Kuntai capsule with HT appears to improve the AFC, AMH and FSH levels of DOR patients. Kuntai capsule alone appears to improve the AFC and FSH levels of DOR patients. However, included trials had methodological quality issues, further standardized research is required.
引用
- Zhang X, Zhang L, Xiong L, et al. Kuntai capsule for the treatment of diminished ovarian reserve: A systematic review and meta-analysis of randomized controlled trials. J Ethnopharmacol. 2024. PMID: 38593964. doi:10.1016/j.jep.2024.118167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。